Ramsey C Cheung

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2496018/publications.pdf

Version: 2024-02-01

98 papers 6,519 citations

172457 29 h-index 77 g-index

98 all docs 98 docs citations 98 times ranked 7910 citing authors

#	Article	IF	CITATIONS
1	Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States. Gastroenterology, 2015, 148, 547-555.	1.3	1,506
2	Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S Hepatology, 2014, 59, 2188-2195.	7.3	616
3	Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis. The Lancet Gastroenterology and Hepatology, 2019, 4, 389-398.	8.1	616
4	Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. The Lancet Gastroenterology and Hepatology, 2020, 5, 739-752.	8.1	481
5	Epidemiology of COVIDâ€19: A systematic review and metaâ€analysis of clinical characteristics, risk factors, and outcomes. Journal of Medical Virology, 2021, 93, 1449-1458.	5.0	450
6	2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2022, 20, 2809-2817.e28.	4.4	255
7	Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States. PLoS ONE, 2017, 12, e0173499.	2.5	203
8	Prospective Multicenter Study of Eligibility for Antiviral Therapy Among 4,084 U.S. Veterans with Chronic Hepatitis C Virus Infection. American Journal of Gastroenterology, 2005, 100, 1772-1779.	0.4	168
9	Viral Hepatitis and Other Infectious Diseases in a Homeless Population. Journal of Clinical Gastroenterology, 2002, 34, 476-480.	2,2	114
10	Epidemiology of hepatitis C virus infection in American veterans. American Journal of Gastroenterology, 2000, 95, 740-747.	0.4	108
11	Integrated Care Increases Treatment and Improves Outcomes of Patients With Chronic Hepatitis C Virus Infection and Psychiatric Illness or Substance Abuse. Clinical Gastroenterology and Hepatology, 2015, 13, 2005-2014.e3.	4.4	93
12	Chronic Hepatitis B Prevalence Among Foreignâ€Born and U.S.â€Born Adults in the United States, 1999â€2016. Hepatology, 2020, 71, 431-443.	7.3	82
13	Diabetes Mellitus Increases Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Virus Patients: A Systematic Review. Digestive Diseases and Sciences, 2016, 61, 636-645.	2.3	80
14	Depression, anxiety, post-traumatic stress, and alcohol-related problems among veterans with chronic hepatitis C. American Journal of Gastroenterology, 2002, 97, 2640-2646.	0.4	75
15	The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with individual and forecasting analysis, 1995–2040. Hepatology International, 2021, 15, 366-379.	4.2	71
16	Cure With Interferonâ€Free Directâ€Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virusâ€Related Hepatocellular Carcinoma From Both East and West. Hepatology, 2020, 71, 1910-1922.	7.3	70
17	Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis. The Lancet Gastroenterology and Hepatology, 2020, 5, 1039-1052.	8.1	70
18	Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis. Journal of Hepatology, 2019, 71, 473-485.	3.7	62

#	Article	IF	Citations
19	Concurrent Obesity, Diabetes, and Steatosis Increase Risk of Advanced Fibrosis Among HCV Patients: A Systematic Review. Digestive Diseases and Sciences, 2015, 60, 2813-2824.	2.3	56
20	The epidemiology of NAFLD in Mainland China with analysis by adjusted gross regional domestic product: a meta-analysis. Hepatology International, 2020, 14, 259-269.	4.2	56
21	Natural History and Hepatocellular Carcinoma Risk in Untreated Chronic Hepatitis B Patients With Indeterminate Phase. Clinical Gastroenterology and Hepatology, 2022, 20, 1803-1812.e5.	4.4	46
22	Diabetes Mellitus, and Not Obesity, Is Associated with Lower Survival Following Liver Transplantation. Digestive Diseases and Sciences, 2015, 60, 1036-1044.	2.3	42
23	Diagnosis Rates of Chronic Hepatitis B in Privately Insured Patients in the United States. JAMA Network Open, 2020, 3, e201844.	5.9	42
24	Can We Predict the Degree of Fibrosis in Chronic Hepatitis C Patients Using Routine Blood Tests in Our Daily Practice?. Journal of Clinical Gastroenterology, 2008, 42, 827-834.	2.2	41
25	Incidences and Determinants of Functional Cure During Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B. Journal of Infectious Diseases, 2021, 224, 1890-1899.	4.0	40
26	The Impact of Chronic Hepatitis C and Comorbid Psychiatric Illnesses on Health-related Quality of Life. Journal of Clinical Gastroenterology, 2006, 40, 528-534.	2.2	39
27	Changes in Renal Function in Patients With Chronic HBV Infection Treated With Tenofovir Disoproxil Fumarate vs Entecavir. Clinical Gastroenterology and Hepatology, 2019, 17, 948-956.e1.	4.4	38
28	HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort. Hepatology International, 2020, 14, 1023-1033.	4.2	38
29	Water-assisted colonoscopy: an international modified Delphi review on definitions and practice recommendations. Gastrointestinal Endoscopy, 2021, 93, 1411-1420.e18.	1.0	33
30	Systematic review with metaâ€analysis: prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B. Alimentary Pharmacology and Therapeutics, 2021, 54, 1100-1109.	3.7	32
31	The impact of pretransplant hepatic encephalopathy on survival following liver transplantation. Liver Transplantation, 2015, 21, 873-880.	2.4	31
32	Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine Practice. Hepatology, 2021, 74, 656-666.	7.3	31
33	Hepatitis C Virus Cure Rates Are Reduced in Patients With Active but Not Inactive Hepatocellular Carcinoma: A Practice Implication. Clinical Infectious Diseases, 2020, 71, 2840-2848.	5.8	30
34	Fatty Liver Index and Development of Cardiovascular Disease: Findings from the UK Biobank. Digestive Diseases and Sciences, 2021, 66, 2092-2100.	2.3	30
35	NASH/Liver Fibrosis Prevalence and Incidence of Nonliver Comorbidities among People with NAFLD and Incidence of NAFLD by Metabolic Comorbidities: Lessons from South Korea. Digestive Diseases, 2021, 39, 634-645.	1.9	29
36	Clinical Features Associated with Survival Outcome in African-American Patients with Hepatocellular Carcinoma. American Journal of Gastroenterology, 2019, 114, 80-88.	0.4	28

#	Article	IF	CITATIONS
37	Poor Adherence to Guidelines for Treatment of ChronicÂHepatitis B Virus Infection at Primary Care and Referral Practices. Clinical Gastroenterology and Hepatology, 2019, 17, 957-967.e7.	4.4	28
38	Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium. Hepatology International, 2019, 13, 587-598.	4.2	27
39	Prevalence of Hepatitis B Vaccination Coverage and Serologic Evidence of Immunity Among US-Born Children and Adolescents From 1999 to 2016. JAMA Network Open, 2020, 3, e2022388.	5.9	26
40	A Nationwide Study of Inpatient Admissions, Mortality, and Costs for Patients with Cirrhosis from 2005 to 2015 in the USA. Digestive Diseases and Sciences, 2020, 65, 1520-1528.	2.3	25
41	Hypomethylation in HBV integration regions aids non-invasive surveillance to hepatocellular carcinoma by low-pass genome-wide bisulfite sequencing. BMC Medicine, 2020, 18, 200.	5.5	25
42	Tenofovir Monotherapy and Tenofovir Plus Entecavir Combination as Rescue Therapy for Entecavir Partial Responders. Digestive Diseases and Sciences, 2012, 57, 3011-3016.	2.3	24
43	Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis. Korean Journal of Internal Medicine, 2019, 34, 296-304.	1.7	23
44	Low Rates of Retention Into Hepatocellular Carcinoma (HCC) Surveillance Program After Initial HCC Screening. Journal of Clinical Gastroenterology, 2019, 53, 65-70.	2.2	23
45	Trends in the Prevalence of Metabolic Dysfunction–Associated Fatty Liver Disease in the United States, 2011–2018. Clinical Gastroenterology and Hepatology, 2022, 20, e610-e613.	4.4	23
46	Substantial gaps in evaluation and treatment of patients with hepatitis B in the US. Journal of Hepatology, 2022, 76, 63-74.	3.7	22
47	Poor Sustained Virological Response in a Multicenter Real-Life Cohort of Chronic Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin plus Telaprevir or Boceprevir. Digestive Diseases and Sciences, 2015, 60, 1045-1051.	2.3	21
48	Birth cohort-specific disparities in hepatocellular carcinoma stage at diagnosis, treatment, and long-term survival. Journal of Hepatology, 2016, 64, 326-332.	3.7	21
49	Fatty liver is not independently associated with the rates of complete response to oral antiviral therapy in chronic hepatitis B patients. Liver International, 2020, 40, 1052-1061.	3.9	20
50	Surveillance of patients with cirrhosis remains suboptimal inÂtheÂUnited States. Journal of Hepatology, 2021, 75, 856-864.	3.7	20
51	Changes in Depressive Symptoms and Impact on Treatment Course Among Hepatitis C Patients Undergoing Interferon- $\hat{1}\pm$ and Ribavirin Therapy: A Prospective Evaluation. American Journal of Gastroenterology, 2011, 106, 2123-2132.	0.4	19
52	Prevalence of Viremic Hepatitis C Virus Infection by Age, Race/Ethnicity, and Birthplace and Disease Awareness Among Viremic Persons in the United States, 1999–2016. Journal of Infectious Diseases, 2020, 221, 408-418.	4.0	19
53	Only one-third of hepatocellular carcinoma cases are diagnosed via screening or surveillance: a systematic review and meta-analysis. European Journal of Gastroenterology and Hepatology, 2020, 32, 406-419.	1.6	19
54	The impact of chronic hepatitis C and co-morbid illnesses on health-related quality of life. Quality of Life Research, 2008, 17, 715-724.	3.1	17

#	Article	IF	Citations
55	Effectiveness of a Screening Program for Hepatitis C. Digestive Diseases and Sciences, 2006, 51, 976-981.	2.3	16
56	Increased Long-term Survival Among Patients With Hepatocellular Carcinoma After Implementation of Model for End-stage Liver Disease Score. Clinical Gastroenterology and Hepatology, 2014, 12, 1534-1540.e1.	4.4	16
57	The Changing Epidemiology of Liver Disease Among US Children and Adolescents From 1999 to 2016. American Journal of Gastroenterology, 2021, 116, 2068-2078.	0.4	16
58	Incidence, Factors, and Patient-Level Data for Spontaneous HBsAg Seroclearance: A Cohort Study of 11,264 Patients. Clinical and Translational Gastroenterology, 2020, 11, e00196.	2.5	15
59	Differential characteristics and outcomes of Asian and nonâ€Asian patients with HBVâ€related hepatocellular carcinoma. Liver International, 2021, 41, 1922-1932.	3.9	15
60	Utilization and Antiviral Therapy in Patients with Chronic Hepatitis C: Analysis of Ambulatory Care Visits in the US. Digestive Diseases and Sciences, 2010, 55, 1744-1751.	2.3	14
61	Antiviral therapy and the development of osteopenia/osteoporosis among Asians with chronic hepatitis B. Journal of Medical Virology, 2019, 91, 1288-1294.	5. O	14
62	Preoperative Endoscopic Findings in Veterans Undergoing Bariatric Surgery: Prevalence and Predictors of Barrett's Esophagus. Obesity Surgery, 2020, 30, 657-663.	2.1	14
63	Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients. Hepatology International, 2021, 15, 71-81.	4.2	14
64	Initial Evaluation, Long-Term Monitoring, and Hepatocellular Carcinoma Surveillance of Chronic Hepatitis B in Routine Practice: A Nationwide US Study. American Journal of Gastroenterology, 2021, 116, 1885-1895.	0.4	14
65	Systematic review and meta-analysis: real-world effectiveness of direct-acting antiviral therapies in chronic hepatitis C genotype 3 in Asia. BMJ Open Gastroenterology, 2018, 5, e000209.	2.7	13
66	National Multicenter Study of HIV Testing and HIV Seropositivity in Patients With Chronic Hepatitis C Virus Infection. Journal of Clinical Gastroenterology, 2006, 40, 732-739.	2.2	12
67	Outcomes of Sequential Therapy With Tenofovir Alafenamide After Long-term Entecavir. American Journal of Gastroenterology, 2021, 116, 1264-1273.	0.4	12
68	Colonoscopy with polypectomy is associated with a low rate of complications in patients with cirrhosis. Endoscopy International Open, 2016, 04, E947-E952.	1.8	11
69	Real-world effectiveness of sofosbuvir plus ribavirin for chronic hepatitis C genotype 2 in Asia: a systematic review and meta-analysis. BMJ Open Gastroenterology, 2018, 5, e000207.	2.7	11
70	More Severe Deficits in Performance Status at Time of Liver Transplant is Associated With Significantly Higher Risk of Death Following Liver Transplantation. Journal of Clinical Gastroenterology, 2019, 53, e392-e399.	2.2	10
71	African-Americans with Cirrhosis Are Less Likely to Receive Endoscopic Variceal Screening Within One Year of Cirrhosis Diagnosis. Journal of Racial and Ethnic Health Disparities, 2018, 5, 860-866.	3.2	8
72	The Impact of Hepatitis C Status on Postoperative Outcome. Anesthesia and Analgesia, 2003, 97, 550-554.	2.2	7

#	Article	IF	CITATIONS
73	High mortality rate in patients with advanced liver disease independent of exposure to general anesthesia. Journal of Clinical Anesthesia, 2005, 17, 172-176.	1.6	7
74	Liver transplantation for non-alcoholic steatohepatitis in Europe: Where do we stand?. Journal of Hepatology, 2019, 71, 240-242.	3.7	7
75	Race/Ethnicity and Insurance-Specific Disparities in In-Hospital Mortality Among Adults with Primary Biliary Cholangitis: Analysis of 2007–2014 National Inpatient Sample. Digestive Diseases and Sciences, 2020, 65, 406-415.	2.3	7
76	Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B study. Hepatology International, 2022, 16, 48-58.	4.2	7
77	Global trends and the impact of chronic hepatitis B and C on <scp>disabilityâ€adjusted</scp> life years. Liver International, 2022, 42, 2145-2153.	3.9	7
78	High hepatitis C virus cure rates with approved interferonâ€free directâ€acting antivirals among diverse mainland Chinese patients including genotypes 3a and 3b. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 767-774.	2.8	6
79	Hepatitis B and renal function: A matched study comparing nonâ€hepatitis B, untreated, treated and cirrhotic hepatitis patients. Liver International, 2019, 39, 655-666.	3.9	5
80	Ethnicity-Specific Differences in Liver Transplant Outcomes Among Adults With Primary Sclerosing Cholangitis: 2005 â \in " 2017 United Network for Organ Sharing/Organ Procurement and Transplantation Network. Journal of Clinical and Experimental Hepatology, $2021, 11, 30-36$.	0.9	5
81	Assessment and Utilization of Rapid Virologic Response in US Veterans With Chronic Hepatitis C. Journal of Clinical Gastroenterology, 2013, 47, 264-270.	2.2	4
82	A population-based US study of hepatitis C diagnosis rate. European Journal of Gastroenterology and Hepatology, 2021, Publish Ahead of Print, .	1.6	4
83	Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine. Clinical Gastroenterology and Hepatology, 2022, 20, 874-885.e4.	4.4	4
84	Positive CAGE Screen Correlates with Cirrhosis in Veterans with Chronic Hepatitis C. Digestive Diseases and Sciences, 2007, 52, 2564-2569.	2.3	3
85	Response to: Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver International, 2020, 40, 3145-3145.	3.9	3
86	Treating the Hardest to Treat: Reframing the Hospital Admission as an Opportunity to Initiate Hepatitis C Treatment. Digestive Diseases and Sciences, 2021, , 1.	2.3	3
87	Low Prevalence of Vaccination or Documented Immunity to Hepatitis A and Hepatitis B Viruses Among Individuals with Chronic Liver Disease. American Journal of Medicine, 2021, 134, 882-892.	1.5	3
88	Letter to the Editor: Prevalence of NAFLD in China: What Did We Learn From the Recent Metaâ€Analysis?. Hepatology, 2019, 70, 2238-2239.	7.3	2
89	Development and Validation of a Risk Score for Liver Cirrhosis Prediction in Untreated and Treated Chronic Hepatitis B. Journal of Infectious Diseases, 2021, 223, 139-146.	4.0	2
90	Diagnostic markers for hepatitis virus infection. Expert Opinion on Medical Diagnostics, 2008, 2, 303-314.	1.6	1

#	Article	IF	CITATIONS
91	Epidemiology, Diagnosis, and Management of Bone Disease in Patients with Chronic HBV Infection. Current Hepatology Reports, 2019, 18, 322-330.	0.9	1
92	In Reply. Archives of Pathology and Laboratory Medicine, 2021, 145, 129b-130.	2.5	1
93	Practice Patterns and Treatment Outcomes in the Management of Chronic Hepatitis C (CHC) Infection in a Large Managed Care Cohort. American Journal of Gastroenterology, 2005, 100, S283.	0.4	1
94	Evaluation of ethnic influence in the application of a hepatocellular carcinoma predictive model for chronic hepatitis C. Journal of Medical Virology, 2021, 93, 6257-6266.	5.0	0
95	ALT Levels in Treatment-Naive, Chronic Hepatitis B Patients with Concurrent Fatty Liver Disease: A US Nationwide Study. Digestive Diseases, 2022, 40, 497-505.	1.9	O
96	County-Level Variation in Cirrhosis-Related Mortality in the US, 1999-2019. JAMA Network Open, 2022, 5, e2146427.	5.9	0
97	Nonalcoholic Fatty Liver Disease in Children: where are we?. Clinical Gastroenterology and Hepatology, 2022, , .	4.4	0
98	Complications of Liver Biopsy. , 0, , 72-75.		0